Skip To Main Content
Alan Barona on Muck Rack

Alan Barona

As seen in: USA Today, Detroit News, NewsNation, The Spokesman-Review, StreetInsider, CP24, ThePrint, Mining, MarketScreener, Global Market Insights - Forex, Futures, Stocks and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Alan

Contact Alan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

US declares end of largest recorded cyclosporiasis outbreak

|
By Alan Barona, Christy Santhosh Verified
| Westlaw Today Verified
We've updated our Privacy Statement. Before you continue, please read our new Privacy Statement and familiarize yourself with the terms.
Open in Who Shared View Duplicates (205) Issue with article?

CBS picks new '60 Minutes' leader from outside TV news

|
By Harshita Mary Varghese Verified, Alan Barona, Rod Nickel
| Detroit News Verified
TV PLUS Harshita Mary Varghese Reuters May 28, 2026, 6:49 p.m. ET View Comments CBS News named on Thursday journalist and author Nick Bilton as executive producer of news show "60 Minutes," marking the first time the show has tapped a leader from outside traditional television news. Bilton is the fifth executive producer in the show's history.
Open in Who Shared View Duplicates (200) Issue with article?

WHO identifies Ebola treatments, vaccines be tested in trials amid outbreak

|
By Siddhi Mahatole Verified, Alan Barona, Shreya Biswas
| Detroit News Verified
WORLD Siddhi Mahatole Reuters May 28, 2026, 6:05 p.m. ET View Comments The World Health Organization recommended prioritizing three experimental treatments for the Bundibugyo strain of Ebola, including Mapp Biopharmaceutical's MBP134, Regeneron's REGN.O maftivimab and Gilead Sciences' GILD.O antiviral remdesivir. The WHO said on Thursday the drugs and other candidate vaccines should be evaluated in clinical trials to generate data on their use.
Open in Who Shared View Duplicates (206) Issue with article?
See all 308 articles